Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011, Article ID 937561, 5 pages
http://dx.doi.org/10.1155/2011/937561
Clinical Study

Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria

Department of Urology, Eberhard Karls University Tuebingen, Hoppe Seyler Straβe 3, 72076 Tuebingen, Germany

Received 29 August 2011; Accepted 28 September 2011

Academic Editor: Peter E. Clark

Copyright © 2011 Joerg Hennenlotter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Lotan, A. M. Kamat, M. P. Porter et al., “Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology,” Cancer, vol. 115, no. 18, pp. 4096–4103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Babjuk, W. Oosterlinck, R. Sylvester et al., “EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update,” European Urology, vol. 59, no. 6, pp. 997–1008, 2011. View at Publisher · View at Google Scholar
  3. S. F. Shariat, J. A. Karam, Y. Lotan, and P. I. Karakiewizc, “Critical evaluation of urinary markers for bladder cancer detection and monitoring,” Reviews in Urology, vol. 10, pp. 120–135, 2008. View at Google Scholar
  4. Y. Lotan, S. F. Shariat, B. J. Schmitz-Dräger et al., “Considerations on implementing diagnostic markers into clinical decision making in bladder cancer,” Urologic Oncology, vol. 28, no. 4, pp. 441–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. I. Budman, W. Kassouf, and J. R. Steinberg, “Biomarkers for detection and surveillance of bladder cancer,” Journal of the Canadian Urological Association, vol. 2, no. 3, pp. 212–221, 2008. View at Google Scholar · View at Scopus
  6. L. E. Ponsky, S. Sharma, L. Pandrangi et al., “Screening and monitoring for bladder cancer: refining the use of NMP22,” Journal of Urology, vol. 166, no. 1, pp. 75–78, 2001. View at Google Scholar · View at Scopus
  7. M. P. Raitanen, E. Kaasinen, O. Lukkarinen et al., “Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer,” Urology, vol. 57, no. 4, pp. 680–684, 2001. View at Google Scholar · View at Scopus
  8. S. Sharma, C. D. Zippe, L. Pandrangi, D. Nelson, and A. Agarwal, “Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat,” Journal of Urology, vol. 162, no. 1, pp. 53–57, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. G. D. Friedman, P. R. Carroll, E. V. Cattolica, and R. A. Hiatt, “Can hematuria be a predictor as well as a symptom or sign of bladder cancer?” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 12, pp. 993–996, 1996. View at Google Scholar · View at Scopus
  10. B. Pesch, M. Nasterlack, F. Eberle et al., “The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines,” The British Journal of Urology International, vol. 108, no. 4, pp. 546–552, 2011. View at Publisher · View at Google Scholar
  11. N. Atsu, S. Ekici, O. O. Oge, A. Ergen, G Hasçelik, and H Ozen, “False-positive results of the NMP22 test due to hematuria,” Journal of Urology, vol. 167, no. 2 I, pp. 555–558, 2002. View at Google Scholar · View at Scopus
  12. O. Oge, D. Kozaci, and H. Gemalmaz, “The BTA stat test is nonspecific for hematuria: an experimental hematuria model,” Journal of Urology, vol. 167, no. 3, pp. 1318–1319, 2002. View at Google Scholar · View at Scopus
  13. L. Sagnak, H. Ersoy, O. Gucuk, U. Ozok, and H. Topaloglu, “Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria,” Urology International, vol. 87, no. 1, pp. 35–41, 2011. View at Google Scholar
  14. Y. Lotan, K. Elias, R. S. Svatek et al., “Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker,” Journal of Urology, vol. 182, no. 1, pp. 52–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Tritschler, S. Scharf, A. Karl et al., “Validation of the diagnostic value of NMP22® BladderChek® test as a marker for bladder cancer by photodynamic diagnosis,” European Urology, vol. 51, no. 2, pp. 403–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. F. Shariat, M. J. Marberger, Y. Lotan et al., “Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer,” Journal of Urology, vol. 176, no. 3, pp. 919–926, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Kinders, T. Jones, R. Root et al., “Complement factor H or a related protein is a marker for transitional cell cancer of the bladder,” Clinical Cancer Research, vol. 4, no. 10, pp. 2511–2520, 1998. View at Google Scholar · View at Scopus
  18. T. Yokoyama, R. Sekigawa, T. Hayashi et al., “The clinical efficacy of Bladder Chek NMP22 in urothelial cancer,” Rinsho Byori, vol. 52, no. 3, pp. 199–203, 2004. View at Google Scholar · View at Scopus
  19. C. Schwentner, J. Hennenlotter, U. Kuehs et al., “Hematuria: helpful or misleading for the early detection of transitional cell carcinoma—results from a cohort of 2008 patients,” Journal of Urology, vol. 183, supplement 1, no. 4, Article ID e454, 2010. View at Google Scholar
  20. C. E. Barbieri, E. K. Cha, and T. F. Chromecki, “Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial,” The British Journal of Urology International. In press. View at Publisher · View at Google Scholar